AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05758857 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: Guidelines-based healthy eating
Description: One-on-one phone/virtual counselling from a registered dietitian to change dietary habits to be in line with Canada's Food Guide.
Study NCT05758857 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Stretching exercise
Description: Twice weekly virtual instructor-led whole-body stretching class.
Study NCT06223802 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: biodex training
Description: women group with a number of 29 women receiving 3-time biodex training per week, every time will be 10 minutes for 12 weeks
Study NCT04736745 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IPN59011
Description: Powder and solvent for solution for injection
Study NCT04736745 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Azzalure
Description: Powder for solution for injection
Study NCT05442827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR7280 tablets
Description: SHR7280 tablets 300mg for 12 weeks
Study NCT05442827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR7280 tablets
Description: SHR7280 tablets 400mg for 12 weeks
Study NCT05442827 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PlaceboSHR7280 tablets blank preparation
Description: Placebo group: SHR7280 tablets blank preparation for 12 weeks
Study NCT05572489 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: visual pain scale Beck depression scale Pain catastrophizing scale Short Form-36 Standard Mini mental test Montreal cognitive assessment scale
Description: evaluation of pain, fatigue, mood, quality of life, cognitive status
Study NCT05289323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neostigmine Methylsulfate
Description: 0.5 mg ampule (1 ml) will be diluted in 4 ml dextrose 5% to make a solution of 100 μg/ml, 0.2 ml of this solution will be added to 2.5 ml of hyperbaric bupivacaine 0.5 % used for intrathecal injection.
Study NCT05289323 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dextrose 5%/Nacl 0.9% Inj
Description: one ml of normal saline 0.9 % will be mixed with 4 ml dextrose 5 % in the five-milliliter syringe. 0.2 ml of this mixture will be prepared at a one-milliliter identical syringe.
Study NCT04673539 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Spanish version of the Brief-BESTest in stroke patients
Description: Adaptation and validation of the Spanish version of the Brief-BESTest in stroke Patients
Study NCT05877092 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: implants with overdentures
Description: two implants with bar attachment placed in interforaminal of the mandible mandible of the participants, the patients were delivered conventional upper complete denture constructed from heat cured acrylic rein, but in implanted mandibular arch they were received complete overdenture constructed from heat cured acrylic resin for Group I, and complete thermoplastic denture was constructed for Group II.
Study NCT06167109 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: CTV optimized IMRT
Description: The contralateral CTV1 was defined as a subclinical disease consisting of 5mm margin surrounding GTVnx.The CTV2 was defined as a potentially involved regions consisting of 5mm margin surrounding CTV1, and contralateral CTV2 only included the pharyngeal recess.
Study NCT06519188 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nebulization application with 5 ml isotonic sodium chloride
Description: Nebulization application with 5 ml isotonic sodium chloride in the morning and evening for two months.
Study NCT04796350 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AGN1 LOEP treatment
Description: the implantation site is injected with the AGN1 implant material
Study NCT05188651 — intervention group
Intervention type: BEHAVIORAL
Intervention: face masks
Description: wearing face masks
Study NCT05224674 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Extracorporeal Shock Wave Therapy (ESWT)
Description: The ESWT device is product of Elettronica Pagani, Italy.
Study NCT05224674 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Extracorporeal Shock Wave Therapy (ESWT)
Description: The ESWT device is product of Elettronica Pagani, Italy.
Study NCT05042947 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: double-loop clips
Description: a new ligation method using the double-loop clips (D-L clips) technique
Study NCT05042947 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Titanium Clip
Description: the Titanium Clip
Study NCT05942664 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sleep
Description: Sleep will be restricted to 60% normal sleep duration
Study NCT05942664 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep
Description: Sleep will be restricted to 60% normal sleep duration
Study NCT06104098 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: D005 vaginal mousse
Description: D005 Vaginal Mousse is class IIa medical device for treatment of Bacterial Vaginosis.
Study NCT05874622 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VC005 tablets
Description: VC005 groups repeat administration for 4 weeks
Study NCT05874622 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VC005 Tablets Placebo
Description: VC005 placebo groups repeat administration for 4 weeks
Study NCT06006624 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exparel 30 mL
Description: 30 mL Liposomal bupivacaine (Exparel) evenly distributed and administered in adductor canal block
Study NCT06006624 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.5% bupivacaine
Description: 5 cc's of 0.5% bupivacaine evenly distributed and administered in adductor canal
Study NCT06006624 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: 10 mg preservative free Dexamethasone evenly distributed and administered in adductor canal
Study NCT06006624 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: iPACK block
Description: iPACK (Infiltration between the Popliteal artery and Capsule of the Knee) block
Study NCT05464368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]RO-948
Description: Johns Hopkins University has conducted the first in human study in collaboration with Roche for 18F-RO948and found that 18F-RO948isa promising radioligand for imaging tau pathology in AD, showing excellent brain uptake and displaying little off-target binding(22, 17, 34).The injected activity for18F-RO948will be as low as practicable, while still allowing accurate quantification of the PET images.The injected dose of 370MBq(10mCi)has been selected based on the radiation dose estimates for18F-RO948gathered in human subjects provided by Michael Stabin, Ph.D., and in accordance with the principle that radiation doses should be as low as reasonably achievable.~This radiotracer will be manufactured on site in the Mallinckrodt Institute of Radiology Cyclotron Facility, a certified Nuclear Pharmacy.
Study NCT05464368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-MK6240
Description: 18F-MK6240 is an investigational PET radiotracer discovered by Merck Research Laboratories and is being developed by Cerveau Technologies, Inc.,for imaging neurofibrillary tangles (NFTs)in the brains of people withAlzheimerdisease.18F-MK6240 has been reported to exhibit good kinetics with high binding levels to brain regions associated with deposition of neurofibrillary tangles in people with AD(35,36).The tracer has been used to monitor the progression of AD.The injected activity for18F-MK6240 will be as low as practicable, while still allowing accurate quantification of the PET images.The injected dose will be 185MBq(5mCi) has been selected based on the radiation dose estimates gathered in human subjects(37)and in accordance with the principle that radiation doses should be as low as reasonably achievable.~This radiotracer will be manufactured on site in the Mallinckrodt Institute of Radiology Cyclotron Facility, a certified Nuclear Pharmacy.
Study NCT05464368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-GTP1
Description: 18F-GTP1is anInvestigational tau PET radiotracer being developed by Genentech for imaging intraneuronal neurofibrillary tangles in patients with AlzheimerDisease. 18F-GTP1 has been reported to exhibit high affinity and selectively for tau pathology, favorable dosimetry and brain kinetics. Degree of 18F-GTP1-specific binding increased withAD severity, could differentiate diagnostic cohorts, and monitor longitudinal change in tau burden.~18F-GTP1 will be provided from LMI sourced through Illinois or New Jersey certified location.
Study NCT04850014 — intervention group
Intervention type: OTHER
Intervention: Anthropomorphism
Description: Height, weight, body surface area, body mass index, exact age (date of birth or age in days, months and years), falling which year of birth gender
Study NCT04850014 — intervention group
Intervention type: OTHER
Intervention: Relevant clinical datas
Description: Medical history Concomitant medication Paracetamol intake : dosage, delay, context, route of intake Alcohol intake Smoking status (including active and passive exposition or no exposition) Curative treatment / Antidote / purifying treatment received and time of introduction Clinical signs, Acetaminophen concentration in plasma with associated accurate time of sampling (date, hour and time following acetaminophen intake Liver and kindney function assessment by measure measuring plasma concentration of: AST, ALT, Factor V, Prothrombin, APTT, INR, albuminemia, bilirubin, phosphorus, pH, creatitine. And GFR estimation.~Imaging.
Study NCT05114616 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NextSense EEG-enabled earbuds
Description: Each NextSense EEGBud device comes with a universal-fit and/or custom-fit earmold with biometric sensors to detect the EEG, motion (via tri-axial accelerometers), and heart rate. The custom mold is created employing a 3D printer following capture of the geometry unique to each patients' ears with a ring laser scanner to an accuracy of within 0.1 mm. This design process allows for a custom fit and therefore both comfort and complete, consistent contact with the inner surface of the ear canal, providing high quality capture of signals reflecting brain activity, and head, and eye movements. In addition to the custom fit earmold, universal fit earmolds are available as well. The universal fit earmolds were designed also to allow for comfort and consisten contact with the inner surface of the ear canal to provide high quality signal capture of brain activity, and head and eye movements.
Study NCT05114616 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ellcie Healthy Glasses
Description: Ellcie Healthy glasses frames are embedded with multi-modal sensors for measuring eye movements, head movement, and ECG.
Study NCT05669820 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Salovum
Description: Salovum is an eggyolkpowder derived from hens fed with SPC (specially processed cereals) and contains increased amounts of the endogenous protein antisecretory factor.
Study NCT05669820 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo egg yolk powder
Description: Egg yolk powder derived from hen fed with normal feed.
Study NCT04736745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Powder for solution for injection
Study NCT04341688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gargle/Mouthwash
Description: There will be 50 patients in six study groups. Group A (n=10) patients on 10 ml gargle and nasal lavage using 0.2% Povidone-Iodine (Betadiene®) for 20-30 seconds, thrice daily for 6 days.~Group B (n=10) patients will be subjected to 10 ml gargle and nasal lavage using 1% Hydrogen peroxide (ActiveOxy®) for 20-30 seconds, thrice daily for 6 days.~Group C will comprised of (n=10) subjects on 10ml gargle and nasal lavage using Neem extract solution (Azardirachta indica) formulated locally) for 20-30 seconds, thrice daily for 6 days.~Group D (n=10) patients will use 2% hypertonic saline (Plabottle®) gargle and nasal lavage for a similar time period.~Group E (n=10) will serve as positive controls. These will be given simple distilled water gargles and nasal lavage for 20-30 seconds, thrice daily for six days Whereas Group F (n=5) will comprise of negative controls, who will not use any gargles or nasal lavage during study period.
Study NCT04341688 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gargle/Mouthwash
Description: There will be 50 patients in six study groups. Group A (n=10) patients on 10 ml gargle and nasal lavage using 0.2% Povidone-Iodine (Betadiene®) for 20-30 seconds, thrice daily for 6 days.~Group B (n=10) patients will be subjected to 10 ml gargle and nasal lavage using 1% Hydrogen peroxide (ActiveOxy®) for 20-30 seconds, thrice daily for 6 days.~Group C will comprised of (n=10) subjects on 10ml gargle and nasal lavage using Neem extract solution (Azardirachta indica) formulated locally) for 20-30 seconds, thrice daily for 6 days.~Group D (n=10) patients will use 2% hypertonic saline (Plabottle®) gargle and nasal lavage for a similar time period.~Group E (n=10) will serve as positive controls. These will be given simple distilled water gargles and nasal lavage for 20-30 seconds, thrice daily for six days Whereas Group F (n=5) will comprise of negative controls, who will not use any gargles or nasal lavage during study period.
Study NCT04341688 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gargle/Mouthwash
Description: There will be 50 patients in six study groups. Group A (n=10) patients on 10 ml gargle and nasal lavage using 0.2% Povidone-Iodine (Betadiene®) for 20-30 seconds, thrice daily for 6 days.~Group B (n=10) patients will be subjected to 10 ml gargle and nasal lavage using 1% Hydrogen peroxide (ActiveOxy®) for 20-30 seconds, thrice daily for 6 days.~Group C will comprised of (n=10) subjects on 10ml gargle and nasal lavage using Neem extract solution (Azardirachta indica) formulated locally) for 20-30 seconds, thrice daily for 6 days.~Group D (n=10) patients will use 2% hypertonic saline (Plabottle®) gargle and nasal lavage for a similar time period.~Group E (n=10) will serve as positive controls. These will be given simple distilled water gargles and nasal lavage for 20-30 seconds, thrice daily for six days Whereas Group F (n=5) will comprise of negative controls, who will not use any gargles or nasal lavage during study period.
Study NCT05397639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Masupirdine 50 mg
Description: Tablet, Once Daily
Study NCT05397639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Masupirdine 100 mg
Description: Tablet, Once Daily
Study NCT05397639 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo Tablet, Once Daily
Study NCT04706156 — intervention group
Intervention type: BIOLOGICAL
Intervention: COVID-19 Vaccine
Description: Receiving coronavirus disease (COVID-19) vaccine e.g. Pfizer-BioNTech, Moderna, Oxford/AstraZeneca, or Sinovac COVID-19 Vaccine
Study NCT04654078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IN-C004 with water
Description: One time dose of IN-C004 taken with water
Study NCT04654078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IN-C004 without water
Description: One time dose of IN-C004 taken without water
Study NCT04654078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-CAB tab. with water
Description: One time dose of K-CAB tab. taken with water
Study NCT05050656 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duloxetine 60mg
Description: Duloxetine is a selective SNRI prescribed in depression, anxiety, and chronic pain like diabetic neuropathy and fibromyalgia, it acts through central and peripheral pain modulation
Study NCT05050656 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo tablets identical to duloxetine tablets
Study NCT05685537 — intervention group
Intervention type: DRUG
Intervention: Levosimendan
Description: Initiation of levosimendan 48 hours before surgery
Study NCT05141721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GRT-C901
Description: A patient-specific neoantigen cancer vaccine administered via intramuscular (IM) injection as prime and single boost at a dose of 1x10\^12 viral particles 2 times over the course of the first year.
Study NCT05141721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GRT-R902
Description: A patient-specific neoantigen cancer vaccine boost, administered via IM injection at a dose of 30ug 4 times over the course of the first year.
Study NCT05141721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered via intravenous (IV) infusion at a dose of 1680 mg once every 4 weeks.
Study NCT05141721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab will be administered via subcutaneous (SC) injection at a dose of 30 mg with the first dose of GRT-C901 and GRT-R902.
Study NCT05141721 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoropyrimidine plus leucovorin
Description: Fluoropyrimidine (infusional 5-FU or capecitabine) and leucovorin administered as maintenance therapy per standard of care.
Study NCT05141721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoropyrimidine plus leucovorin
Description: Fluoropyrimidine (infusional 5-FU or capecitabine) and leucovorin administered as maintenance therapy per standard of care.
Study NCT05141721 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Bevacizumab administered as maintenance therapy per standard of care.
Study NCT05141721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab administered as maintenance therapy per standard of care.
Study NCT05393141 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: diet and biopsychosocial exercise intervention
Description: dietary intervention: biopsychosocial exercise intervention:
Study NCT05603559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1.1 GBq (30 mCi) of 177Lu-P17-087
Description: All patients were intravenous injected with single dose 1.1 GBq (30 mCi) of 177Lu-P17-087 then monitored at 1.5 hours, 4 hours, 24 hours, 48 hours, 72 hours, 120 hours and 168 hours post-injection.
Study NCT05603559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1.1 GBq (30 mCi) of 177Lu-P17-088
Description: All patients were intravenous injected with single dose 1.1 GBq (30 mCi) of 177Lu-P17-088 then monitored at 1.5 hours, 4 hours, 24 hours, 48 hours, 72 hours, 120 hours and 168 hours post-injection.
Study NCT05398679 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefaclor
Description: cefaclor intravenous 2 gr/day
Study NCT05398679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin Tablets
Description: 500-750 mg/12 hrs (maximum 3g x day)
Study NCT05398679 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciprofloxacin Injection
Description: 1200 mg/day maximum dose IV
Study NCT05398679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clindamycin Oral Capsule
Description: 600 mg/8 hours (maximum 1.800 mg x day)
Study NCT05398679 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clindamycin Injection
Description: 600 mg/8 hours (maximum 1.800 mg x day) IV
Study NCT05398679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dicloxacillin Oral Capsule
Description: 1g/8 hours (maximum 4 gr day)
Study NCT05398679 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dicloxacillin
Description: 1g/8 hours (maximum 4 g x day) IV
Study NCT05398679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fusidic Acid Only Product in Oral Dose Form
Description: 0,750g/12 hours (maximum 1,5 g x day)
Study NCT05398679 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fusidic Acid Only Product in Parenteral Dose Form
Description: 0,75 g/12 hours (maximum 1,5 g x day)
Study NCT05398679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin Oral Tablet
Description: 0.5g/12-24hours (maximum 1 g x day)
Study NCT05398679 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levofloxacin Injection
Description: 0.5g/12-24hours (maximum 1 g x day)
Study NCT05398679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linezolid Oral Tablet
Description: 0,6 g/12 hours (maximum 1200 mg x day)
Study NCT05398679 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linezolid Injectable Product
Description: 0,6 g/12 hours (maximum 1200 mg x day)
Study NCT05398679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin tablet
Description: 0,4 g/day (maximum 400 mg x day)
Study NCT05398679 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin Injectable Product
Description: 0,4 g/day (maximum 400 mg x day)
Study NCT05398679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin Only Product in Oral Dose Form
Description: 0,3-0,5 g/12 hours (maximum 1200 mg x day)
Study NCT05398679 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifampicin Only Product in Parenteral Dose Form
Description: 0,3-0,6 g/12 hours (maximum 1200 mg x day)
Study NCT05398679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfamethoxazole / Trimethoprim Oral Tablet [Bactrim]
Description: sulfamethoxazole 1600 mg/trimethoprin 320 mg (maximum x day)
Study NCT05398679 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulfamethoxazole / Trimethoprim Injectable Product
Description: sulfamethoxazole 1600 mg/trimethoprin 320 mg (maximum x day)